AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca share-based compensation expense ($M) ($M)
Form 20-F Note 30 — Employee Costs
Latest, FY2025
719
Period ended Dec 31, 2025
Change on a year earlier
+8.9%
660 in FY2024
History
11 years
Since FY2015
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Share-based compensation expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 719 | +8.9% | Form 20-F FY2025 Annual Report ↗ |
| FY2024 | Dec 31, 2024 | 660 | +14.0% | Form 20-F FY2025 Annual Report ↗ |
| FY2023 | Dec 31, 2023 | 579 | -6.5% | Form 20-F FY2025 Annual Report ↗ |
| FY2022 | Dec 31, 2022 | 619 | +0.7% | Form 20-F FY2024 Annual Report ↗ |
| FY2021 | Dec 31, 2021 | 615 | +122.0% | Form 20-F (filed 2022-02-22) ↗ |
| FY2020 | Dec 31, 2020 | 277 | +6.9% | Form 20-F (filed 2021-02-16) ↗ |
| FY2019 | Dec 31, 2019 | 259 | +18.3% | Form 20-F (filed 2020-03-03) ↗ |
| FY2018 | Dec 31, 2018 | 219 | -0.5% | Form 20-F (filed 2019-03-05) ↗ |
| FY2017 | Dec 31, 2017 | 220 | -8.7% | Form 20-F (filed 2018-03-06) ↗ |
| FY2016 | Dec 31, 2016 | 241 | +14.2% | Form 20-F (filed 2018-03-06) ↗ |
| FY2015 | Dec 31, 2015 | 211 | – | Form 20-F (filed 2018-03-06) ↗ |
Cite this data
StockData. (2026). AstraZeneca Share-based compensation expense ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/emp_cost_sbc
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.